HOME
ABOUT US
JOIN MECFA
MEMBERS
OUR IMPACT
GIVE BREATH
NEWS
WHAT IS CF
MENU
Middle East CF Association
Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds
VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE
A case for improved carrier screening
Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data
Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS
Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis
CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics
The search for molecular glue in targeted disease control
Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says
Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p
Annual Scientific Conference
The Heartbreaking Reality of Cystic Fibrosis Care in Iraq: A Mother's Plea for Help
MECFA supports CF patients in Tunisia
International disparities in diagnosis and treatment access for cystic fibrosis
Philip Hopewell Prize for Global Respiratory Health Research
South Africans take on big pharma for access to ‘miracle’ cystic fibrosis drug
MECFA launches campaign to help people with CF in Gaza and the West Bank, Palestine
Ministry of Health unveils national electronic registry for cystic fibrosis patients
MECFA Jordan Project report
Conquering chronic lung infection in cystic fibrosis patients
Comentarios